Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Executive V.P., Operations | June 04, 2007 | June 05, 2007 |
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | January 06, 2026 | January 08, 2026 |
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Director | June 15, 2026 | June 17, 2026 |
| Pfenex Inc.PFNX · Entity 146052 | Director | May 05, 2017 | May 08, 2017 |
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Director | May 30, 2019 | June 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date June 04, 2007 · Filed June 05, 2007
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 132,661 |
Reported balance
After 2007-06-04 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2007-06-04 · Exercise / conversion · Acquired 10,000 · Balance 132,661 |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 127,518 |
Reported balance
After 2007-06-04 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2007-06-04 · Sale · Disposed 5,143 · Balance 127,518 |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 117,518 |
Reported balance
After 2007-06-04 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2007-06-04 · Sale · Disposed 10,000 · Balance 117,518 |
| NQSOSEC Table II · derivative / convertible security · Conversion / exercise price $38.36 · Expires 2009-07-01 | IndirectBy Family Trust | 27,391 |
Reported balance
After 2007-06-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2007-06-04 · Exercise / conversion · Disposed 10,000 · Balance 27,391 F1: This option exercisable as follows: 30,000 shares on July 1, 2003; 30,000 shares on July 1, 2004; 30,000 shares on July 1, 2005; 30,000 shares on July 1, 2006; and 27,391 shares in July 1, 2007. |
| Common StockSEC Table I · non-derivative | Direct | 6,668 |
Reported balance
Holding disclosure · report date 2007-06-04 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 6,668 |
| Common StockSEC Table I · non-derivative | IndirectBy Irrevocable Trust | 1,000 |
Reported balance
Holding disclosure · report date 2007-06-04 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This option exercisable as follows: 30,000 shares on July 1, 2003; 30,000 shares on July 1, 2004; 30,000 shares on July 1, 2005; 30,000 shares on July 1, 2006; and 27,391 shares in July 1, 2007.
ANAPTYSBIO, INC
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.91 · Expires 2036-01-05 | Direct | 5,500 |
Reported balance
After 2026-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-06 · Grant · Acquired 5,500 · Balance 5,500 F1: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,000 |
Reported balance
After 2026-01-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-06 · Grant · Acquired 4,000 · Balance 4,000 F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
First Tracks Biotherapeutics, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,995 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 6,030 · Balance 10,995 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Exercise / conversion · Disposed 6,030 · Balance 0 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Pfenex Inc.
Report date May 05, 2017 · Filed May 08, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.92 · Expires 2027-05-05 | Direct | 18,000 |
Reported balance
After 2017-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-05 · Grant · Acquired 18,000 · Balance 18,000 F1: One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the "Annual Meeting") held after May 5, 2017, subject to the reporting person's continuing service through the date of the Annual Meeting. Notwithstanding the foregoing, one hundred percent (100%) of the shares subject to the option shall vest and become exercisable as of immediately prior to a Change in Control (as such term is defined in the Issuer's 2014 Equity Incentive Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the "Annual Meeting") held after May 5, 2017, subject to the reporting person's continuing service through the date of the Annual Meeting. Notwithstanding the foregoing, one hundred percent (100%) of the shares subject to the option shall vest and become exercisable as of immediately prior to a Change in Control (as such term is defined in the Issuer's 2014 Equity Incentive Plan).
Sienna Biopharmaceuticals, Inc.
Report date May 30, 2019 · Filed June 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2029-05-30 | Direct | 25,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PORTOLA PHARMACEUTICALS INC
Report date July 02, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 1
1 source rowRow 1 · 2020-07-02 · Disposition to issuer · Disposed 13,194 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 2
1 source rowRow 2 · 2020-07-02 · Disposition to issuer · Disposed 7,281 · Balance 0 F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.94 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-02 · Disposition to issuer · Disposed 44,991 · Balance 0 F4: In connection with the Merger, these options were accelerated and canceled without payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
F4: In connection with the Merger, these options were accelerated and canceled without payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 17, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | Exercise / conversionRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001184627-26-000007 · form4-06172026_040612.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | Exercise / conversionCommon Stock | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001184627-26-000007 · form4-06172026_040612.xml · nonDerivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001184627-26-000005 · form4-05142026_040509.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2036-05-11 F3 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · balance_after: In addition to the options to purchase a total of 42,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 97,827 shares of common stock, which options vest according to their terms. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001184627-26-000005 · form4-05142026_040509.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 12, 2026 Filed Jun 12, 2026 20:09 UTC Amendment | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001184627-26-000006 · form4a-06122026_080633.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2036-05-11 F3 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 12, 2026 Filed Jun 12, 2026 20:09 UTC Amendment | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001184627-26-000006 · form4a-06122026_080633.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 13 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F8 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F8 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 12 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F7 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F7 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 11 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-01-06 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 10 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2035-01-06 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 9 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2034-01-02 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 10,600 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 8 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2033-01-05 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 7 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 6 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-02-09 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 5 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-02-11 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $18.43 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 4 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-02-07 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 5,507 | $0.00 Strike: $31.82 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 3 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,507 Underlying: Common Stock · 5,507 shares Expires 2028-03-04 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $31.82 | $0.00 |
DisclosureSEC source: 0001184627-26-000004 · form4-04222026_040411.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-03-04 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001184627-26-000001 · form4-01082026_090118.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $43.91 | $0.00 |
DisclosureSEC source: 0001184627-26-000001 · form4-01082026_090118.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-01-05 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:07 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,015 | $23.97 | $72,269.55 |
DisclosureSEC source: 0001415889-25-017820 · form4-06202025_080627.xml · nonDerivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,965 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F2 · shares: Shares sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units on June 15, 2025. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017591 · form4-06172025_100602.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017591 · form4-06172025_100602.xml · nonDerivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:31 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001041 · form4-01072025_100131.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:31 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001415889-25-001041 · form4-01072025_100131.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2035-01-06 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 7, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 21:23 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,950 | $23.17 | $45,181.50 |
DisclosureSEC source: 0001415889-24-018032 · form4-06242024_090611.xml · nonDerivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,950 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 00:18 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017512 · form4-06192024_120627.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 00:18 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017512 · form4-06192024_120627.xml · nonDerivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:53 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001045 · doc4.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:53 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001209191-24-001045 · doc4.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 3, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002878 · doc4.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,900 Underlying: Common Stock · 3,900 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 00:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 10,600 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001209191-23-002878 · doc4.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2033-01-05 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:43 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-22-009323 · doc4.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 02:26 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-21-010513 · doc4.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:26 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040311 · doc4.xml · derivative · entry 4 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,991 shares Expires not disclosed F4 · derivative.exercise_price: In connection with the Merger, these options were accelerated and canceled without payment. F4 · price: In connection with the Merger, these options were accelerated and canceled without payment. F4 · derivative.exercise_date: In connection with the Merger, these options were accelerated and canceled without payment. F4 · derivative.expiration_date: In connection with the Merger, these options were accelerated and canceled without payment. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:26 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,377 | $0.06 Strike: $11.94 | $682.62 |
DisclosureSEC source: 0001209191-20-040311 · doc4.xml · derivative · entry 3 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,377 shares Expires 2030-06-11 F3 · price: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F3 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:26 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerRestricted Stock Units | 7,281 | $18.00 | $131,058.00 |
DisclosureSEC source: 0001209191-20-040311 · doc4.xml · nonDerivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · acquired: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 16:26 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | Disposition to issuerCommon Stock | 13,194 | $18.00 | $237,492.00 |
DisclosureSEC source: 0001209191-20-040311 · doc4.xml · nonDerivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 18:54 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 11,377 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-20-036764 · doc4.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,377 Underlying: Common Stock · 11,377 shares Expires 2030-06-11 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 12, 2020 Filed Jun 15, 2020 18:54 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 7,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036764 · doc4.xml · nonDerivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2021, subject to the Reporting Person's Continuous Services (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 22:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $16.56 | $0.00 |
DisclosureSEC source: 0001209191-20-009309 · doc4.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-02-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 12, 2020, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 17:19 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,991 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001209191-19-037438 · doc4.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,991 Underlying: Common Stock · 6,991 shares Expires 2029-06-12 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 17:19 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 4,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037438 · doc4.xml · nonDerivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,194 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 19:24 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 25,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001562180-19-003238 · primarydocument.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:08 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $68.89 | $0.00 |
DisclosureSEC source: 0001209191-19-009006 · doc4.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 8, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 18:00 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $42.81 | $0.00 |
DisclosureSEC source: 0001209191-18-036762 · doc4.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-07 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document |
| June 08, 2018 Filed Jun 8, 2018 18:00 UTC | PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036762 · doc4.xml · nonDerivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSUs fully vest on March 1, 2019, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 21:41 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0001562180-18-002848 · primarydocument.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2018-06-01 F1 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 22:22 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (right to buy) · Derivative | 5,507 | $0.00 Strike: $118.97 | $0.00 |
DisclosureSEC source: 0001209191-18-017377 · doc4.xml · derivative · entry 2 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,507 Underlying: Common Stock · 5,507 shares Expires 2028-03-04 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 11 equal monthly installments beginning on April 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 22:22 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $118.97 | $0.00 |
DisclosureSEC source: 0001209191-18-017377 · doc4.xml · derivative · entry 1 FENTON DENNIS M · CIK 0001184627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-03-04 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 36 equal monthly installments beginning on April 5, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.